Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition) 公告 2024-12-16 08:50:00 Written By Kym Kilbourne Title: Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition) Abstract The "Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition)" is jointly formulated by the Multidisciplinary Diagnosis and Treatment Professional Committee of the Chinese Anti-Cancer Association and the Oncology Endocrinology Professional Committee of the Chinese Anti-Cancer Association. It aims to standardize the application of oncology organoids in precision treatment and ensure their quality control. This consensus is based on global research data and provides guidance on the clinical application and quality control of drug sensitivity testing using oncology organoids. Development of Oncology Organoid Technology The development of organoid technology has provided a new avenue for the development of human cancer models. Oncology organoids retain the histopathological characteristics, genetic features, and molecular biological features of the original tumor, serving as a novel testing model for new anticancer drugs and providing a basis for personalized precision treatment through drug sensitivity testing and feedback on patient clinical responses. Main Content of the Expert Consensus Introduction to Oncology Organoids Oncology organoids are three-dimensional structures cultured from patient tumor tissues that can grow efficiently while retaining the characteristics of the original tumor. These organoids show great potential in drug development, regenerative medicine, and personalized healthcare. Application of Oncology Organoid Diagnostic and Treatment Platforms Target Population High-throughput drug screening tests using organoids are recommended for patients with various primary and metastatic solid malignant tumors, including those in the respiratory, digestive, and urogenital systems. Application Scenarios Organoid models can be used for patients with solid tumors at different treatment modalities or stages, especially for those with drug-resistant, refractory, or recurrent tumors. Ethics and Informed Consent Research activities involving human-derived organoids should be reviewed by an ethics committee and obtain informed consent from patients. Scope of Clinical Intervention Drug sensitivity testing of oncology organoids can guide clinical medication decisions, especially in cases where standard drug treatment regimens are contraindicated or result in severe adverse reactions. General Process of Oncology Organoid Drug Sensitivity Testing Includes steps such as patient consent, tumor sample collection, organoid construction and culture, growth status assessment, organoid identification, drug sensitivity testing, and evaluation of test results. Quality Control of Oncology Organoid Drug Sensitivity Testing Involves quality control processes for tissue cell acquisition, organoid amplification and cryopreservation, and identification. High-Throughput Drug Sensitivity Testing of Oncology Organoids and Prospects The application scenarios of high-throughput drug sensitivity testing of oncology organoids in new drug development, preclinical research, and near-clinical research, as well as the implementation foundation. Conclusion Oncology organoid technology provides new models and methods for precision oncology treatment. Although the technology is still in its developmental stages, it has shown potential in predicting patient responses to treatment. Future prospective clinical studies will further validate the testing efficacy of organoid models and provide higher-level evidence-based medical evidence for the clinical application of oncology organoid drug sensitivity testing. Kym Kilbourne
Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition) 公告 2024-12-16 08:50:00 Written By Kym Kilbourne Title: Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition) Abstract The "Chinese Expert Consensus on Quality Control Standards for Oncology Organoid Diagnostic and Treatment Platforms (2022 Edition)" is jointly formulated by the Multidisciplinary Diagnosis and Treatment Professional Committee of the Chinese Anti-Cancer Association and the Oncology Endocrinology Professional Committee of the Chinese Anti-Cancer Association. It aims to standardize the application of oncology organoids in precision treatment and ensure their quality control. This consensus is based on global research data and provides guidance on the clinical application and quality control of drug sensitivity testing using oncology organoids. Development of Oncology Organoid Technology The development of organoid technology has provided a new avenue for the development of human cancer models. Oncology organoids retain the histopathological characteristics, genetic features, and molecular biological features of the original tumor, serving as a novel testing model for new anticancer drugs and providing a basis for personalized precision treatment through drug sensitivity testing and feedback on patient clinical responses. Main Content of the Expert Consensus Introduction to Oncology Organoids Oncology organoids are three-dimensional structures cultured from patient tumor tissues that can grow efficiently while retaining the characteristics of the original tumor. These organoids show great potential in drug development, regenerative medicine, and personalized healthcare. Application of Oncology Organoid Diagnostic and Treatment Platforms Target Population High-throughput drug screening tests using organoids are recommended for patients with various primary and metastatic solid malignant tumors, including those in the respiratory, digestive, and urogenital systems. Application Scenarios Organoid models can be used for patients with solid tumors at different treatment modalities or stages, especially for those with drug-resistant, refractory, or recurrent tumors. Ethics and Informed Consent Research activities involving human-derived organoids should be reviewed by an ethics committee and obtain informed consent from patients. Scope of Clinical Intervention Drug sensitivity testing of oncology organoids can guide clinical medication decisions, especially in cases where standard drug treatment regimens are contraindicated or result in severe adverse reactions. General Process of Oncology Organoid Drug Sensitivity Testing Includes steps such as patient consent, tumor sample collection, organoid construction and culture, growth status assessment, organoid identification, drug sensitivity testing, and evaluation of test results. Quality Control of Oncology Organoid Drug Sensitivity Testing Involves quality control processes for tissue cell acquisition, organoid amplification and cryopreservation, and identification. High-Throughput Drug Sensitivity Testing of Oncology Organoids and Prospects The application scenarios of high-throughput drug sensitivity testing of oncology organoids in new drug development, preclinical research, and near-clinical research, as well as the implementation foundation. Conclusion Oncology organoid technology provides new models and methods for precision oncology treatment. Although the technology is still in its developmental stages, it has shown potential in predicting patient responses to treatment. Future prospective clinical studies will further validate the testing efficacy of organoid models and provide higher-level evidence-based medical evidence for the clinical application of oncology organoid drug sensitivity testing. Kym Kilbourne
